|
|
|
|
| LEADER |
01598nam a2200265 u 4500 |
| 001 |
EB002191699 |
| 003 |
EBX01000000000000001329164 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
240105 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian drug expert committee recommendation: Vortioxetine (Trintellix --Lundbeck Canada Inc.)
|h Elektronische Ressource
|b indication: for the treatment of major depressive disorder in adults
|
| 246 |
3 |
1 |
|a Drug reimbursement recommendation Vortioxetine (Trintellix)
|
| 246 |
3 |
1 |
|a Vortioxetine (Trintellix --Lundbeck Canada Inc.)
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, February 2020
|
| 300 |
|
|
|a 1 PDF file (9 pages)
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 500 |
|
|
|a "Final."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK563051
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The CADTH Canadian Drug Expert Committee recommends that vortioxetine be reimbursed for the treatment of major depressive disorder in adults if the following conditions are met. Conditions for Reimbursement: 1. Reimburse in a similar manner to other antidepressants for the treatment of patients with major depressive disorder. 2. The drug plan cost of treatment with vortioxetine should not exceed the drug plan cost of the least costly antidepressant currently reimbursed
|